v3.26.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 8 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 11, 2025
Sep. 30, 2026
Sep. 11, 2025
Sep. 30, 2026
Revenues:          
Total revenues $ 255 $ 1,288 $ 2,696 $ 4,222 $ 8,397
Operating expenses:          
Fund management and administration 282 1,251 1,583 4,250 4,496
Employee compensation and benefits 18,720 3,151 15,633 7,222 45,000
General and administrative expense 445 871 6,669 4,229 19,035
Impairment of medical device research and development intangible asset 0 0 14,650 0 14,650
Marketing and advertising 18 68 86 231 281
Depreciation and amortization 12 43 78 149 254
Total operating expenses 19,477 5,384 38,699 16,081 83,716
Investment gains (losses):          
Net unrealized gain (loss) on digital assets, at fair value (10,133) 0 533,697 0 9,888
Net unrealized gain on investments in preferred equity, at fair value 0 0 8,833 0 3,361
Other investment gain (loss) 0 0 1,497 0 (1,304)
Other derivative loss (14,731) 0 0 0 0
Total investment gains (losses) (24,864) 0 544,027 0 11,945
Net operating income (loss) (44,086) (4,096) 508,024 (11,859) (63,374)
Other income (expense):          
Other income 68 10 1,008 586 2,489
Interest expense on long-term notes payable, at fair value 0     0 (282)
Change in fair value on long-term notes payable, at fair value 0     0 (2,464)
Loss on extinguishment of debt 0     0 (8,431)
Loss on change in fair value of bitcoin held as collateral under Coinbase Loan 0     0 (2,594)
Goodwill and intangible asset impairment (140,785) 0 0 0 0
Transaction costs (7,484) (10,280) 0 (15,717) (6,525)
Bargain purchase gain 0     0 66,704
Total other income (expense) (148,201) (10,270) 1,008 (15,131) 48,897
Net income (loss) before income taxes (192,287) (14,366) 509,032 (26,990) (14,477)
Income tax benefit (expense) 0 0 0 0 0
Net income (loss) (192,287) (14,366) 509,032 (26,990) (14,477)
Dividends on preferred stock 0 0 (34,231) 0 (73,894)
Net income (loss) attributable to common stockholders (192,287) (14,366) 474,801 (26,990) (88,371)
Net income (loss) attributable to common stockholders $ (192,287) $ (14,366) $ 474,801 $ (26,990) $ (88,371)
Weighted average number of common shares outstanding:          
Basic (in shares) [1] 43,617,459 2,325,783 89,080,303 2,299,243 75,429,254
Diluted (in shares) [1] 43,617,459 2,325,783 90,534,798 2,299,243 75,429,254
Net income (loss) per common share:          
Basic (in USD per share) [1] $ (4.41) $ (6.18) $ 5.33 $ (11.74) $ (1.17)
Diluted (in USD per share) [1] $ (4.41) $ (6.18) $ 5.24 $ (11.74) $ (1.17)
Investment advisory fees          
Revenues:          
Total revenues $ 246 $ 1,283 $ 1,559 $ 4,187 $ 4,418
Medical device revenues          
Revenues:          
Total revenues 0 0 1,133 0 3,891
Other revenue          
Revenues:          
Total revenues $ 9 $ 5 $ 4 $ 35 $ 88
[1] Basic and diluted earnings per common share for Class A and Class B common stock are the same.